Browsing Tag
rintatolimod
2 posts
Can Ampligen improve immunotherapy durability in recurrent ovarian cancer treatment?
Can AIM ImmunoTech Inc.’s Ampligen improve immunotherapy durability in ovarian cancer? Explore the Phase 2 data and industry impact.
May 9, 2026
How orphan drug status and patent protection shape Ampligen’s commercial and regulatory outlook
Discover how orphan drug status and long-dated patents could shape Ampligen’s regulatory path and commercial value in pancreatic cancer.
February 7, 2026